Department on Stem Cell Aging, University of Ulm, Ulm, Germany.
Hepatology. 2011 May;53(5):1608-17. doi: 10.1002/hep.24217.
Telomere shortening impairs liver regeneration in mice and is associated with cirrhosis formation in humans with chronic liver disease. In humans, telomerase mutations have been associated with familial diseases leading to bone marrow failure or lung fibrosis. It is currently unknown whether telomerase mutations associate with cirrhosis induced by chronic liver disease. The telomerase RNA component (TERC) and the telomerase reverse transcriptase (TERT) were sequenced in 1,121 individuals (521 patients with cirrhosis induced by chronic liver disease and 600 noncirrhosis controls). Telomere length was analyzed in patients carrying telomerase gene mutations. Functional defects of telomerase gene mutations were investigated in primary human fibroblasts and patient-derived lymphocytes. An increased incidence of telomerase mutations was detected in cirrhosis patients (allele frequency 0.017) compared to noncirrhosis controls (0.003, P value 0.0007; relative risk [RR] 1.859; 95% confidence interval [CI] 1.552-2.227). Cirrhosis patients with TERT mutations showed shortened telomeres in white blood cells compared to control patients. Cirrhosis-associated telomerase mutations led to reduced telomerase activity and defects in maintaining telomere length and the replicative potential of primary cells in culture.
This study provides the first experimental evidence that telomerase gene mutations are present in patients developing cirrhosis as a consequence of chronic liver disease. These data support the concept that telomere shortening can represent a causal factor impairing liver regeneration and accelerating cirrhosis formation in response to chronic liver disease.
端粒缩短会损害小鼠的肝脏再生能力,与慢性肝病患者肝硬化的形成有关。在人类中,端粒酶突变与导致骨髓衰竭或肺纤维化的家族性疾病有关。目前尚不清楚端粒酶突变是否与慢性肝病引起的肝硬化有关。在 1121 名个体(521 名由慢性肝病引起的肝硬化患者和 600 名非肝硬化对照者)中对端粒酶 RNA 成分(TERC)和端粒酶逆转录酶(TERT)进行了测序。在携带端粒酶基因突变的患者中分析了端粒长度。在原代人成纤维细胞和患者来源的淋巴细胞中研究了端粒酶基因突变的功能缺陷。与非肝硬化对照组相比,肝硬化患者中端粒酶基因突变的发生率增加(等位基因频率 0.017 对 0.003,P 值 0.0007;相对风险 [RR] 1.859;95%置信区间 [CI] 1.552-2.227)。与对照组患者相比,携带 TERT 突变的肝硬化患者白细胞中端粒缩短。与肝硬化相关的端粒酶突变导致端粒酶活性降低,以及维持端粒长度和培养中原代细胞复制潜能的缺陷。
本研究首次提供了实验证据,证明端粒酶基因突变存在于因慢性肝病而发展为肝硬化的患者中。这些数据支持这样一种概念,即端粒缩短可能是一种因果因素,损害肝脏再生能力并加速慢性肝病引起的肝硬化形成。